Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243278 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1ADRB2OPRK1 | |
| SCHEMBL1841051 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1ADRB2OPRK1 | |
| SCHEMBL22533940 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1ADRB2OPRK1 | |
| SCHEMBL13949318 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1ADRB2OPRK1 | |
| SCHEMBL12662666 | 0.88 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1MAPTLMNA | |
| SCHEMBL4239581 | 0.85 | KDM4E (0.36) | KDM4EALDH1A1L3MBTL1ADRB2ADRB1 | |
| SCHEMBL4239577 | 0.85 | KDM4E (0.36) | KDM4EALDH1A1L3MBTL1ADRB2ADRB1 | |
| SCHEMBL4670053 | 0.81 | AOC3 (0.44) | KDM4EALDH1A1L3MBTL1ADRB3MAPK1 | |
| SCHEMBL4615842 | 0.80 | ADRB1 (0.47) | ADRB2ADRB1ADRB3MAPK1CYP3A4 | |
| SCHEMBL4615835 | 0.80 | ADRB1 (0.47) | ADRB2ADRB1ADRB3MAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479838-B2 | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220220102-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-07-14 | — | — | US | disclosed |
| US-20220220102-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-07-14 | — | — | US | disclosed |
| EP-3953350-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | The United States of America, as Represented by The Department of Health and Human Services (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210785-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210785-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-1848709-B1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | PFIZER LTD (GB) | 2011-05-18 | — | — | EP | disclosed |
| US-7498329-B2 | Salt form of dopamine agonist | PFIZER INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | PFIZER, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1848709-A1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | Pfizer Limited (GB) | 2007-10-31 | — | — | EP | disclosed |
| EP-1758862-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | Pfizer Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20060183740-A1 | Novel salt form of a dopamine agonist | PFIZER INC | 2006-08-17 | — | — | US | disclosed |
| WO-2006082511-A1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | PFIZER LIMITED (GB) | 2006-08-10 | — | — | WO | disclosed |
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005115985-A1 | AMINOPYRIDINE DERIVATIVES AS SELECTIVE DOPAMINE D3 AGONISTS | PFIZER LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220102-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | DRD3, ADRB3, VDR | KDM4E 4472/4885ALDH1A1 2173/4885L3MBTL1 2037/4885 |
| US-20050288270-A1 | New aminopyridine derivatives and their use as pharmaceuticals | DRD2, DRD1, DRD3 | KDM4E 2165/4885ALDH1A1 792/4885L3MBTL1 4477/4885 |
| US-12479838-B2 | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof | DRD3, ADRB3, VDR | KDM4E 4472/4885ALDH1A1 2173/4885L3MBTL1 2037/4885 |
| US-20090005354-A1 | New Amino Derivatives and Their Use as Pharmaceuticals | DRD2, DRD1, DRD3 | KDM4E 2273/4885ALDH1A1 1067/4885L3MBTL1 4182/4885 |
| US-20060183740-A1 | Novel salt form of a dopamine agonist | SLC6A3, CHRNA5, TACR2 | KDM4E 2433/4885ALDH1A1 2367/4885L3MBTL1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.